JP2021534253A5 - - Google Patents

Info

Publication number
JP2021534253A5
JP2021534253A5 JP2021532537A JP2021532537A JP2021534253A5 JP 2021534253 A5 JP2021534253 A5 JP 2021534253A5 JP 2021532537 A JP2021532537 A JP 2021532537A JP 2021532537 A JP2021532537 A JP 2021532537A JP 2021534253 A5 JP2021534253 A5 JP 2021534253A5
Authority
JP
Japan
Prior art keywords
approximately
pharmaceutical composition
composition according
bendamustine
organic
Prior art date
Application number
JP2021532537A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2020035806A5 (https=
JP2021534253A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IB2019/056903 external-priority patent/WO2020035806A1/en
Publication of JP2021534253A publication Critical patent/JP2021534253A/ja
Publication of JPWO2020035806A5 publication Critical patent/JPWO2020035806A5/ja
Publication of JP2021534253A5 publication Critical patent/JP2021534253A5/ja
Priority to JP2024086001A priority Critical patent/JP2024109878A/ja
Withdrawn legal-status Critical Current

Links

JP2021532537A 2018-08-17 2019-08-14 液体ベンダムスチン医薬組成物 Withdrawn JP2021534253A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024086001A JP2024109878A (ja) 2018-08-17 2024-05-28 液体ベンダムスチン医薬組成物

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201862764975P 2018-08-17 2018-08-17
US62/764,975 2018-08-17
US201862723725P 2018-08-28 2018-08-28
US62/723,725 2018-08-28
US201962815376P 2019-03-08 2019-03-08
US62/815,376 2019-03-08
PCT/IB2019/056903 WO2020035806A1 (en) 2018-08-17 2019-08-14 Liquid bendamustine pharmaceutical compositions

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024086001A Division JP2024109878A (ja) 2018-08-17 2024-05-28 液体ベンダムスチン医薬組成物

Publications (3)

Publication Number Publication Date
JP2021534253A JP2021534253A (ja) 2021-12-09
JPWO2020035806A5 JPWO2020035806A5 (https=) 2022-08-10
JP2021534253A5 true JP2021534253A5 (https=) 2022-08-10

Family

ID=69525233

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021532537A Withdrawn JP2021534253A (ja) 2018-08-17 2019-08-14 液体ベンダムスチン医薬組成物
JP2024086001A Withdrawn JP2024109878A (ja) 2018-08-17 2024-05-28 液体ベンダムスチン医薬組成物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024086001A Withdrawn JP2024109878A (ja) 2018-08-17 2024-05-28 液体ベンダムスチン医薬組成物

Country Status (7)

Country Link
US (1) US12246007B2 (https=)
EP (1) EP3836921B1 (https=)
JP (2) JP2021534253A (https=)
AU (1) AU2019321089A1 (https=)
CA (1) CA3108321A1 (https=)
ES (1) ES3055021T3 (https=)
WO (1) WO2020035806A1 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2022508807A (ja) 2018-10-16 2022-01-19 ユーエス・ナノ・フード・アンド・ドラッグ・インコーポレーテッド 腫瘍内注射製剤
US11730815B2 (en) 2018-11-26 2023-08-22 Good Health, Llc Stable liquid pharmaceutical compositions comprising bendamustine
US11752165B2 (en) * 2020-04-13 2023-09-12 US Nano Food & Drug, Inc Basic chemotherapeutic intratumour injection formulation
CN121465991A (zh) * 2020-04-15 2026-02-06 卡希夫生物科学有限公司 卡非佐米的稳定的即稀释型制剂
GB202118175D0 (en) 2021-12-15 2022-01-26 Arecor Ltd Novel composition
US11707450B1 (en) * 2022-03-03 2023-07-25 Slayback Pharma Llc Stable pharmaceutical compositions of bendamustine
CN118415976A (zh) * 2024-05-09 2024-08-02 深圳开悦生命科技有限公司 多环化合物注射剂及其制备方法

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8436190B2 (en) 2005-01-14 2013-05-07 Cephalon, Inc. Bendamustine pharmaceutical compositions
AR072777A1 (es) 2008-03-26 2010-09-22 Cephalon Inc Formas solidas de clorhidrato de bendamustina
EP2326306A1 (en) 2008-09-25 2011-06-01 Cephalon, Inc. Liquid formulations of bendamustine
PL3158991T3 (pl) 2010-01-28 2021-09-27 Eagle Pharmaceuticals, Inc. Preparaty bendamustyny
US20130210878A1 (en) 2012-01-24 2013-08-15 Innopharma, Inc. Bendamustine compositions and methods therefore
CA2867295C (en) 2012-03-20 2020-08-11 Eagle Pharmaceuticals, Inc. Formulations of bendamustine
PL2827863T3 (pl) 2012-03-20 2019-07-31 Eagle Pharmaceuticals, Inc. Ciekła kompozycja do zastosowania w sposobie leczenia stanów reagujących na bendamustynę u pacjentów wymagających obniżonych objętości do podawania
US20160235717A1 (en) * 2013-10-11 2016-08-18 Luitpold Pharmaceuticals, Inc. Bendamustine pharmaceutical compositions
WO2016005995A2 (en) 2014-07-10 2016-01-14 Leiutis Pharmaceuticals Pvt. Ltd. Glycol free stable liquid compositions of bendamustine
WO2016059590A1 (en) 2014-10-16 2016-04-21 Piramal Enterprises Limited Stable injectable composition of small molecule drugs and process for its preparation
US9603930B2 (en) 2014-12-04 2017-03-28 Navinta, Llc Liquid bendamustine formulation
CN105726472B (zh) * 2016-03-25 2019-12-13 南京康玻斯医药科技有限公司 苯达莫司汀药剂组合物及应用
US20190151234A1 (en) * 2016-04-05 2019-05-23 Leiutis Pharmaceuticals Pvt. Ltd. Stable liquid pharmaceutical formulations of bendamustine
US10905677B2 (en) * 2016-08-31 2021-02-02 Navinta, Llc Bendamustine solution formulations

Similar Documents

Publication Publication Date Title
JP2021534253A5 (https=)
CN102164579B (zh) 苯达莫司汀的液体配制品
CN104203235B (zh) 苯达莫司汀的制剂
JP2015506989A5 (https=)
AR086115A1 (es) Formulaciones parenterales mejoradas de agentes farmaceuticos lipofilos y los metodos para la preparacion y el uso de las mismas
JP2024109878A (ja) 液体ベンダムスチン医薬組成物
US20130102551A1 (en) Antibiotic compositions
US9603930B2 (en) Liquid bendamustine formulation
JPWO2020035806A5 (https=)
AR085273A1 (es) Formulacion liquida libre de propelente que comprende una droga antimuscarinica
US8809308B2 (en) Enema composition for treatment of ulcerative colitis having long term stability
WO2017175098A1 (en) Stable liquid pharmaceutical formulations of bendamustine
US20240009199A1 (en) Pemetrexed formulations
PE20040303A1 (es) Formulacion parenteral liquida estable de parecoxib
US20230226033A1 (en) Stable formulation of efinaconazole
Kapetanovic et al. Pharmacokinetics and enhanced bioavailability of candidate cancer preventative agent, SR13668 in dogs and monkeys
JPWO2018056336A1 (ja) ペメトレキセド製剤
CN104203224A (zh) 含有2-氨基-3-(4-溴苯甲酰基)苯乙酸的水性组合物
AU2023202089B2 (en) Pemetrexed formulations
JP2017057202A (ja) ボルテゾミブ含有凍結乾燥医薬組成物およびその製造方法
US20150320680A1 (en) Injectable composition containing chlorothiazide
WO2021192471A1 (ja) ペメトレキセド製剤
WO2021192472A1 (ja) ペメトレキセド製剤
CN105451731A (zh) 含有经稳定化的2-氨基-3-(4-溴苯甲酰基)苯乙酸的水性组合物
JP2011032220A (ja) エダラボン液剤